Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 117

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 117
---
 determine the order of priority for using the proceeds, as well as the amount and sources of other funds needed. Pending our application of the net proceeds from this offering, we plan to invest such proceeds in short-term, investment-grade, interest-bearing securities and depositary institutions. DIVIDEND POLICY We have never declared or paid any cash dividends to our shareholders of our Common Shares, and we do not anticipate or intend to pay cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors, or our Board, in compliance with applicable legal requirements and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable law and other factors that our Board may deem relevant. The Business Corporations Act (British Columbia), as amended, or the BCBCA, imposes further restrictions on our ability to declare and pay dividends. See “Description of Share Capital—Dividends” for additional information. Payment of dividends may be subject to Canadian withholding taxes. See “Taxation — Material Canadian Federal Income Tax Considerations” below for additional information. 71 CAPITALIZATION The following table sets forth our cash and our capitalization as of July 31, 2025:

| ● | on an actual basis; and |

| ● | on pro forma basis, giving effect to the issuance                                                                                        
 of (i) Promissory Notes from September 2025 in the aggregate principal amount of $2.5 million, of which an aggregate of $2.5 million     
 of outstanding amounts due under the Promissory Notes were converted into 5,171,460 Common Shares at conversion prices between $0.251    
 and $0.818 during October 2025 and November 2025, (ii) the issuance and sale of 3,942,365 Common Shares and/or pre-funded warrants       
 in the First November 2025 Offering at a public offering price of $0.20 per Common Share and $0.1999 per pre-funded warrant for net      
 proceeds of $738,000, after deducting offering expenses payable by us, (iii) the issuance and sale of 5,509,768 Common Shares and/or     
 pre-funded warrants in the Second November 2025 Offering at a public offering price of $0.25 per Common Share and $0.2499 per pre-funded 
 warrant for net proceeds of approximately